Prevalence and risk factors of steatosis after liver transplantation and patient outcomes
Open Access
- 28 December 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 22 (5) , 644-655
Abstract
Steatosis occurs frequently after liver transplantation (LT). We aimed to determine the prevalence of steatosis in adult LT recipients, to determine the effects of significant (>33%; grades 2‐3) steatosis on patient survival, and to identify risk factors for the development of significant steatosis and its effect on fibrosis progression. We retrospectively examined 2360 posttransplant biopsies of 548 LT recipients. Survival was compared between patients with significant steatosis and those with grades 0‐1 steatosis. Patients with significant steatosis were compared to controls without steatosis (grade 0) for clinical and laboratory factors and fibrosis progression. Steatosis was found in 309 (56.4%) patients, including 93 (17.0%) patients with significant steatosis. Steatohepatitis (nonalcoholic fatty liver disease activity score ≥ 5) was diagnosed in 57 (10.4%) patients. The prevalence of steatosis increased from 30.3% at 1 year to 47.6% at 10 years after LT (P < 0.001). Survival times did not differ between groups (P = 0.29). On multivariate analysis of pretransplant factors and initial immunosuppression (IS), alcohol‐induced cirrhosis (P < 0.001) and high body mass index (BMI; P = 0.002) were associated with the development of significant steatosis, whereas increased levels of alkaline phosphatase (P = 0.01) and mycophenolate mofetil given initially (P = 0.009) appeared to protect against significant steatosis. On multivariate analysis of posttransplant factors, high BMI (P < 0.001), serum triglycerides (P < 0.001), alcohol consumption (P = 0.005), and type 2 diabetes mellitus (P = 0.048) were associated with significant steatosis, whereas high creatinine (P = 0.02) appeared to protect against significant steatosis. Significant steatosis was not associated with a higher fibrosis stage (P = 0.62). Posttransplant steatosis affects 56.4% of LT recipients, and the prevalence increases with time after LT. Recipient factors and types of IS affect the risk for significant steatosis, which is not associated with a higher fibrosis stage or worse patient survival. Liver Transplantation 22 644‐655 2016 AASLD.Keywords
Funding Information
- (Ministry of Health, Czech Republic) for development of research organization (00023001)
This publication has 30 references indexed in Scilit:
- Epidemiological survey and risk factor analysis of fatty liver disease of adult residents, Beijing, ChinaJournal of Gastroenterology and Hepatology, 2013
- Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008Clinical Gastroenterology and Hepatology, 2011
- Fatty liver index and mortality: The cremona study in the 15th year of follow-upHepatology, 2011
- NAFLD Recurrence in Liver Transplant RecipientsTransplantation, 2011
- Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosisJournal of Gastroenterology, 2010
- Recurrent Disease Following Liver Transplantation for Nonalcoholic Steatohepatitis CirrhosisLiver Transplantation, 2009
- Lower Serum Creatinine Is a New Risk Factor of Type 2 DiabetesDiabetes Care, 2009
- Prevention of diabetes: effect of mycophenolate mofetil and anti-CD25 on onset of diabetes in the DRBB ratPediatric Diabetes, 2008
- Steatosis: Co-factor in Other Liver Diseases *Hepatology, 2005
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005